EUCTR2021-005383-22-DE进行中（未招募）1 期
Cognitive Function, Depression, Anxiety, and Quality of Life in Chronic Heart Failure Patients with Iron Deficiency with and without Anaemia: Effects of Intravenous Iron (Ferric Derisomaltose) - CogFer Study
niversitätsmedizin Göttingen0 个研究点目标入组 36 人开始时间: 2022年3月30日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1.The Patient is willing and able to participate and provides written informed consent;
- •2.Age = 18 years and < 85;
- •3.NYHA II-III functional class due to stable symptomatic chronic HF and all of the following;
- •4.Three months without cardiac hospitalization;
- •5.Patients in NYHA II: acute care admission or emergency room visit for worsening HF at least once within 24 months prior to start of treatment, but not in the last three months;
- •6.Appropriate dose of medical therapy for HF (such as ACEi, ARB, ß-blocker, oral diuretics, MRA, ARNI, ivabradine) consistent with prevailing local and international CV guidelines.
- •7.No dose changes of HF drugs during the last 2 weeks (exception for diuretics);
- •8.No introduction of a new HF drug class during the last 4 weeks;
- •9.LVEF = 40 % for both groups of NYHA functional classes; documented within the last 12 months prior to screening;
- •10.At screening or Visit 1, significantly raised plasma levels of natriuretic peptides (NT-proBNP = 600 pg/ml or BNP = 150 pg/ml) or if they have been hospitalized for HF within the previous 12 months, a NT-proBNP = 400 pg/ml or BNP of at least 100 pg/ml or by patients with atrial fibrillation and HF, a NT-proBNP = 900 pg/ml;
- •11.Screening ferritin < 100 ng/ml OR ferritin 100-299 ng/ml if TSAT < 20 %;
- •12.Hb: =10 < 15.0 g/dl
- •13.Patient must be able to perform the 6 minute walking distance und handgrip strength measurements according to investigator judgment;
- •14.Mild cognitive impairment according to MoCA Test.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 26
排除标准
- •1.Clinical signs and symptoms of infection or C-reactive protein > 20 mg/l;
- •2.Clinically significant bleeding and subject at an immediate need of transfusion;
- •3.Active malignancy with exception of basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia;
- •4.History of erythropoetin, IV or oral iron therapy, and blood transfusion in previous 4 weeks;
- •5.Chronic liver disease and/or screening alanine transaminase (ALT) or aspartate transaminase (AST) above three times the upper limit of the normal range;
- •6.Vitamin B12 and/or serum folate deficiency. If deficiency is corrected, patients may be re-screened for inclusion;
- •7.Haemolytic anaemia and other forms of anaemia not based on ID (e.g. other microcytic anaemia, pernicious anaemia);
- •8.Known HIV/AIDS;
- •9.Currently receiving systemic chemotherapy and/or radiotherapy;
- •10.Renal replacement therapy (previous, current or planned within the next 6 month) or haemodialysis;
- •11.Severe valvular or left ventricular outflow obstruction disease, obstructive cardiomyopathy;
- •12. Atrial fibrillation/flutter with a mean ventricular response rate in rest > 100 bpm;
- •13.Uncontrolled hypertension with blood pressure > 160/100 mmHg;
- •14.Acute coronary syndrome (STEMI, NSTEMI or unstable angina pectoris), transient ischaemic attack or stroke within the last 3 months;
- •15.Coronary-artery bypass graft, percutaneous intervention (cardiac, cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including thoracic and cardiac surgery, within the last 3 months or planned during the study;
- •16.Implantation of CRT/ICD within the past 3 months or planned during the study;
- •17.Subject is pregnant (e.g., positive ß-hCG test) or is breast feeding;
- •18.Women in childbearing age and not using medically acceptable effective contraception refer to CTFG*;
- •19.History of acquired iron overload or hemochromatosis (or a first relative with hemochromatosis);
- •20.Hypersensitivity to the active substance, to FDI or any of its excipients;
- •21.Earlier hypersensitivity to parental iron preparations or a history of allergic disorders;
- •22.History of severe asthma, eczema or other atopic allergy;
- •23.History of immune or inflammatory conditions (e.g. systemic lupus erythematosus, rheumatoid arthritis);
- •24.Concurrent immunosuppressive therapy;
- •25.Psychosis or dementia (latter assessed by DemTect);
- •26.Prescribed anti-dementia medication
- •27.Diagnosed current severe depressive episode (according to ICD-10-GM).
研究者
相似试验
已完成
不适用
Cognitive coping, depression and anxiety in people with autism spectrum disorderNL-OMON40658Bavo Europoort (Parnassia Groep)115
尚未招募
不适用
Cognitive Dysfunctions in Breast Cancer PatientsCTRI/2022/02/040405Akeeksha Sharma
招募中
不适用
analysis of cognitive function and symptom effected by hearing device fitting in aged patients with hearing impairmentmild cognitive impairment and dementia age-related hearing lossJPRN-UMIN000025213Kyoto University30
已完成
不适用
Idiographic study of Cognitive function, Affect, and Sleep in the ElderlydepressionDementie en amnestische stoornissen (onder psychische stoornissen)affectmemory problemsmoodsleep disorderssleep disturbancescognitive impairments10027946NL-OMON44788niversitair Medisch Centrum Groningen20
招募中
不适用
Relationship between Cognitive Functions and Depression on Diabetes Self-Care Behavior in Older Adult with Type 2 Diabetes: A Cohort-Study with 1-Year-Follow UpOlder Adults with type 2 diabetesT2DM, elderly, self-Care behavior, cognitionTCTR20201111001Physical Therapy Faculty207